Diltiazem Hydrochloride Tablets are calcium channel blockers that effectively dilate the coronary arteries in the epicardium and subendocardium for the relief of spontaneous angina pectoris or coronary artery spasm induced by ergometrine. Reduce cardiac oxygen demand, increase exercise tolerance and relieve exertive angina by slowing heart rate and lowering blood pressure; It can relax the vascular smooth muscle, reduce the resistance of peripheral blood vessels and reduce blood pressure.
Efficacy function
Angina pectoris and exertional angina caused by coronary artery spasm. hypertension Hypertrophic cardiomyopathy.
Usage.
Take orally, 1-2 tablets each time, 3-4 times a day, before meals or before going to bed. If the dose needs to be increased, the daily dose should not exceed 360 mg, but should be taken under the guidance of a doctor.
taboo
1. Pathological sinus node syndrome without pacemaker.
2. Patients with grade II or III ATrioventricular block without pacemaker.
3. Systolic blood pressure is lower than 12kPa(90mmHg), heart rate is lower than 50 beats/min.
4. People who are allergic to this product.
5.Patients with congestive heart failure.
Adverse reactions
Swelling, headache, nausea, dizziness, rash, and weakness may occur with diltiazem hydrochloride.
Rarely (incidence below 1.0%) :
Atrioventricular block, bradycardia, bundle branch block, congestive heart failure, abnormal electrocardiogram (ecg), low blood pressure, heart palpitations, syncope, tachycardia, ventricular premature beat, much dream, forget, depression, abnormal gait, hallucinations, insomnia, nervousness, sleepiness, tremor, anorexia, constipation, diarrhea, taste disorders, indigestion, thirst, vomiting, mild abnormal liver function, petechiae, and is sensitive to light , pruritus, urticaria, erythema multiforme, exfoliative dermatitis, amblyopia, creatine phosphate elevated muscle enzymes, difficulty breathing, nasal congestion, high blood sugar, high uric acid hematic disease, impotence, muscle cramps, polyuria, tinnitus, joint pain, loss of hair, extrapyramidal syndrome, gingival hyperplasia, hemolytic anemia, bleeding time prolonging, leukopenia, purpura, retinopathy, and thrombocytopenia.
The information released is provided as knowledge only for the reference and exchange of industry insiders. No guarantee is given for its accuracy or completeness. You should not use this as a substitute for your own independent judgment, and therefore you do so at your own risk
